ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking

Crit Care. 2020 Jul 31;24(1):475. doi: 10.1186/s13054-020-03195-9.

Chidinma L Onweni¹, Yu Shrike Zhang², Thomas Caulfield^{3

4}, Christopher E Hopkins^{5

6}, De Lisa Fairweather^{7

8}, William D Freeman^{9

10}

¹ Department of Critical Care Medicine, Mayo Clinic, Jacksonville, FL, USA.
² Division of Engineering in Medicine, Brigham and Women's Hospital, Boston, MA, USA.
³ Department of Neurologic Surgery, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL, 32224, USA.
⁴ Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL, USA.
⁵ Brigham and Women's Hospital, Boston, MA, USA.
⁶ InVivo Biosystems, Eugene, OR, USA.
⁷ Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL, USA.
⁸ Department of Immunology, Mayo Clinic, Jacksonville, FL, USA.
⁹ Department of Critical Care Medicine, Mayo Clinic, Jacksonville, FL, USA. freeman.william1@mayo.edu.
¹⁰ Department of Neurologic Surgery, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL, 32224, USA. freeman.william1@mayo.edu.

No abstract available

Keywords: ACE2; ACEI/ARB therapy; COVID-19.

Publication types